Dong-A turns its eyes to Chinese market

Published: 2003-03-04 06:56:00

Updated: 2003-03-04 06:56:00

Dong-A says it newly established Wuhan Donghe Pharma, a joint venture firm, with Donghe Corporation under the same 50:50 equity ratio of investment amounting to a total $250,000 in an effort to market Dong-A's own drugs including Panpyrin, etc. in the Chinese market.

According to Dong-A Pharm, Panpyrin is scheduled to be marketed in 2005 after completion of related license procedures in the ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.